Note: Patrick Deane holds shares in Gensight Biologics (EPA: SIGHT). A trial with damagingly positive results Gensight Biologics, a company researching – among other things – the movement of mitochondrial genetic information to the nucleus to treat hereditary genetic diseases (a strategy that could also have an impact on aging according to the SENS Research…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD